Pfizer reports gene therapy data from Phase Ib DMD trial
PF-06939926 is an experimental gene therapy being developed to treat Duchenne muscular dystrophy.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
